[ FDA ENFORCEMENT INTELLIGENCE ]
Learn from the record. Every FDA recall is a quality signal.
Live drug, device & food recall data from the FDA (openFDA enforcement) — food spanning dietary supplements, cosmetics & animal food — mapped to the GxP quality domains SPEQ assesses, so you can see where control breaks down across every regulated industry.
1,000
Total recalls
217
Class I (most serious)
167
Drug
515
Device
318
Food / supplement / cosmetic
Last 12 months · latest report 2026-07-22 · source: openFDA enforcement
RECALLS BY CLASSIFICATION · MONTHLY
RECALL REASONS BY QUALITY DOMAIN
Domain mapping is a SPEQ interpretation of the FDA recall reason, not an official FDA classification.
315 matching recalls
| Date | Class | Firm | Reason | Quality domain |
|---|---|---|---|---|
| 2026-06-24 | Class II | Medline Industries, LPZ-2485-2026 | During an internal review, Medline identified representative samples did not meet applicable performance specifications. Identified issues include irregularities in catheter surface finish, instances where the catheter connector detached prematurely from the catheter funnel, and limited cases where the catheter outer diameter did not meet specification. | Validation & Qualification |
| 2026-06-24 | Class II | Accriva Diagnostics, Inc.Z-2460-2026 | Assayed Whole blood control contains labeling with incorrect performance range. | Validation & Qualification |
| 2026-06-24 | Class II | Medline Industries, LPZ-2505-2026 | During an internal review, Medline identified representative samples did not meet applicable performance specifications. Identified issues include irregularities in catheter surface finish, instances where the catheter connector detached prematurely from the catheter funnel, and limited cases where the catheter outer diameter did not meet specification. | Validation & Qualification |
| 2026-06-24 | Class II | Medline Industries, LPZ-2497-2026 | During an internal review, Medline identified representative samples did not meet applicable performance specifications. Identified issues include irregularities in catheter surface finish, instances where the catheter connector detached prematurely from the catheter funnel, and limited cases where the catheter outer diameter did not meet specification. | Validation & Qualification |
| 2026-06-24 | Class II | PAI Holdings LLCD-0592-2026 | Does Not Meet USP or OTC Monograph: Product did not meet the Over-the-Counter (OTC) Monograph M023 | Validation & Qualification |
| 2026-06-17 | Class II | Philips North America LlcZ-2354-2026 | System was delivered without the required Seismic kit for Wall Stand VS2, which is designed to prevent damage and ensure stability of the Wall Stand VS2 during seismic events. | Validation & Qualification |
| 2026-06-17 | Class II | BERLIN HEART GMBHZ-2320-2026 | Blood pump inner package expiration date does not match the outer-correct expiration date, which may lead to delays in surgical procedures. | Validation & Qualification |
| 2026-06-17 | Class II | Ascend Laboratories, LLCD-0597-2026 | Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis | Validation & Qualification |
| 2026-06-17 | Class II | Breckenridge Pharmaceutical, Inc.D-0583-2026 | CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit | Validation & Qualification |
| 2026-06-17 | Class II | Golden State Medical Supply Inc.D-0587-2026 | Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint. | Validation & Qualification |
| 2026-06-17 | Class II | Breckenridge Pharmaceutical, Inc.D-0582-2026 | CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit | Validation & Qualification |
| 2026-06-17 | Class III | Fresenius Kabi USA, LLCD-0581-2026 | Failed Impurities/Degradations Specifications | Validation & Qualification |
| 2026-06-10 | Class II | Advanced Bionics, LLCZ-2283-2026 | Due to incorrect shelf-life expiration date. | Validation & Qualification |
| 2026-06-10 | Class II | Baxter Healthcare CorporationZ-2262-2026 | Affected lots may contain incorrect 0.8-micron filters. Use of a 0.8-micron filter in place of the validated 3-micron filter may lead to reduced flow efficiency, incomplete or slower transfers of ingredients, or system alarms. This issue may lead to clinical effects such as electrolyte imbalance, metabolic instability, delayed recovery, etc. | Validation & Qualification |
| 2026-06-10 | Class III | Sato Pharmaceutical Inc.H-0892-2026 | Product does not meet label claim for Vitamin E. | Validation & Qualification |
| 2026-06-10 | Class II | Lannett Company Inc.D-0584-2026 | Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint. | Validation & Qualification |
| 2026-06-10 | Class II | Asclemed USA Inc.D-0555-2026 | CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit. | Validation & Qualification |
| 2026-06-10 | Class II | Ascend Laboratories, LLCD-0556-2026 | Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications | Validation & Qualification |
| 2026-06-03 | Class III | AbbVie Inc.D-0551-2026 | Failed Stability Specifications | Validation & Qualification |
| 2026-06-03 | Class III | AVEVA Drug Delivery Systems, Inc.D-0550-2026 | Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability testing of individual units. | Validation & Qualification |
| 2026-05-27 | Class II | PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.Z-2229-2026 | The deaeration hose in X-ray tube cooling units type CU3101, manufactured between February 2016 and May 2020, may degrade over time, potentially resulting in oil leakage. Oil leakage may affect the cooling performance of the X-ray tube. When the oil flow drops below a certain threshold, the system automatically switches to low-dose fluoroscopy and displays the message Low load fluoroscopy flavor selected: Tube cooler problem . This condition cannot be resolved by restarting the system. | Validation & Qualification |
| 2026-05-27 | Class III | Sagent PharmaceuticalsD-0539-2026 | Failed Impurities/Degradation Specifications | Validation & Qualification |
| 2026-05-27 | Class II | IntegraDose Compounding Services LLCD-0548-2026 | Subpotent Drug | Validation & Qualification |
| 2026-05-27 | Class II | PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.Z-2228-2026 | The deaeration hose in X-ray tube cooling units type CU3101, manufactured between February 2016 and May 2020, may degrade over time, potentially resulting in oil leakage. Oil leakage may affect the cooling performance of the X-ray tube. When the oil flow drops below a certain threshold, the system automatically switches to low-dose fluoroscopy and displays the message Low load fluoroscopy flavor selected: Tube cooler problem . This condition cannot be resolved by restarting the system. | Validation & Qualification |
| 2026-05-27 | Class II | PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.Z-2227-2026 | The deaeration hose in X-ray tube cooling units type CU3101, manufactured between February 2016 and May 2020, may degrade over time, potentially resulting in oil leakage. Oil leakage may affect the cooling performance of the X-ray tube. When the oil flow drops below a certain threshold, the system automatically switches to low-dose fluoroscopy and displays the message Low load fluoroscopy flavor selected: Tube cooler problem . This condition cannot be resolved by restarting the system. | Validation & Qualification |
Data: U.S. FDA openFDA enforcement API. Quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Recall details are as reported by the FDA.